Accounts Payable, Current of AYTU BIOPHARMA, INC from 31 Aug 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
AYTU BIOPHARMA, INC quarterly Accounts Payable, Current in USD history and change rate from 31 Aug 2011 to 31 Dec 2025.
  • AYTU BIOPHARMA, INC Accounts Payable, Current for the quarter ending 31 Dec 2025 was $14,259,000, a 22% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Payable, Current, Quarterly (USD)
Accounts Payable, Current, YoY Quarterly Change (%)

AYTU BIOPHARMA, INC Quarterly Accounts Payable, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $14,259,000 +$2,560,000 +22% 31 Dec 2025 10-Q 03 Feb 2026 2026 Q2
Q3 2025 $12,342,000 -$1,171,000 -8.7% 30 Sep 2025 10-Q 13 Nov 2025 2026 Q1
Q2 2025 $10,601,000 +$287,000 +2.8% 30 Jun 2025 10-Q 03 Feb 2026 2026 Q2
Q1 2025 $12,041,000 +$1,566,000 +15% 31 Mar 2025 10-Q 14 May 2025 2025 Q3
Q4 2024 $11,699,000 +$1,226,000 +12% 31 Dec 2024 10-Q 12 Feb 2025 2025 Q2
Q3 2024 $13,513,000 30 Sep 2024 10-Q 13 Nov 2024 2025 Q1
Q2 2024 $10,314,000 -$3,164,000 -23% 30 Jun 2024 10-K 23 Sep 2025 2025 FY
Q1 2024 $10,475,000 31 Mar 2024 10-Q 15 May 2024 2024 Q3
Q4 2023 $10,473,000 31 Dec 2023 10-Q 14 Feb 2024 2024 Q2
Q2 2023 $13,478,000 30 Jun 2023 10-K 26 Sep 2024 2024 FY
Q2 2021 $19,255,000 +$7,615,000 +65% 30 Jun 2021 10-K 28 Sep 2021 2021 FY
Q1 2021 $16,528,646 +$9,572,555 +138% 31 Mar 2021 10-Q 17 May 2021 2021 Q3
Q4 2020 $7,157,208 -$2,441,359 -25% 31 Dec 2020 10-Q 11 Feb 2021 2021 Q2
Q3 2020 $5,773,768 +$3,141,126 +119% 30 Sep 2020 10-Q 12 Nov 2020 2021 Q1
Q2 2020 $11,640,000 +$9,506,478 +446% 30 Jun 2020 10-K 28 Sep 2021 2021 FY
Q1 2020 $6,956,091 +$4,824,840 +226% 31 Mar 2020 10-Q 15 May 2020 2020 Q3
Q4 2019 $9,598,567 +$7,226,782 +305% 31 Dec 2019 10-Q 14 Feb 2020 2020 Q2
Q3 2019 $2,632,642 +$520,859 +25% 30 Sep 2019 10-Q 14 Nov 2019 2020 Q1
Q2 2019 $2,133,522 +$13,850 +0.65% 30 Jun 2019 10-K 06 Oct 2020 2020 FY
Q1 2019 $2,131,251 -$1,068,072 -33% 31 Mar 2019 10-Q 14 May 2019 2019 Q3
Q4 2018 $2,371,785 -$1,043,069 -31% 31 Dec 2018 10-Q 14 May 2019 2019 Q2
Q3 2018 $2,111,783 +$451,019 +27% 30 Sep 2018 10-Q 07 Nov 2018 2019 Q1
Q2 2018 $2,119,672 -$100,728 -4.5% 30 Jun 2018 10-K 26 Sep 2019 2020 FY
Q1 2018 $3,199,323 +$1,790,370 +127% 31 Mar 2018 10-Q 14 May 2018 2018 Q3
Q4 2017 $3,414,854 31 Dec 2017 10-Q 08 Feb 2018 2018 Q2
Q3 2017 $1,660,764 30 Sep 2017 10-Q 09 Nov 2017 2018 Q1
Q2 2017 $2,220,400 -$102,205 -4.4% 30 Jun 2017 10-K 06 Sep 2018 2018 FY
Q1 2017 $1,408,953 31 Mar 2017 10-Q 11 May 2017 2017 Q3
Q2 2016 $2,322,605 30 Jun 2016 10-K 31 Aug 2017 2017 FY
Q1 2015 $546,346 +$535,233 +4816% 31 Mar 2015 10-Q 19 May 2015 2015 Q3
Q4 2014 $3,580* -$9,183 30 Nov 2014 10-Q 12 Jan 2015 2015 Q1
Q3 2014 $310* -$6,532 31 Aug 2014 10-Q 15 Apr 2015 2015 Q2
Q2 2014 $649,504 +$642,105 +8678% 30 Jun 2014 10-Q 19 May 2015 2015 Q3
Q1 2014 $11,113 -$2,905 -21% 28 Feb 2014 10-Q 11 Apr 2014 2014 Q2
Q4 2013 $12,763 +$716 +5.9% 30 Nov 2013 10-Q 10 Jan 2014 2014 Q1
Q3 2013 $6,842 +$999 +17% 31 Aug 2013 10-K 26 Nov 2014 2013 FY
Q2 2013 $7,399 +$3,273 31 May 2013 10-Q 28 Jun 2013 2013 Q3
Q1 2013 $14,018 +$10,121 28 Feb 2013 10-Q 15 Apr 2013 2013 Q2
Q4 2012 $12,047 +$6,592 +121% 30 Nov 2012 10-Q 14 Jan 2013 2013 Q1
Q3 2012 $5,843 +$5,513 31 Aug 2012 10-K 26 Nov 2014 2013 FY
Q2 2012 $4,126* 31 May 2012 10-Q 26 Jun 2012 2012 Q3
Q1 2012 $3,897* 29 Feb 2012 10-Q 12 Apr 2012 2012 Q2
Q4 2011 $5,455 30 Nov 2011 10-Q 23 Dec 2011 2012 Q1
Q3 2011 $330* 31 Aug 2011 10-K 29 Nov 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.